The National Organization for Rare Disorders (NORD) gave its 2017 Industry Innovation Award to Intercept Pharmaceuticals for the company’s primary biliary cholangitis (PBC) drug …
Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic…
Nonalcoholic steatohepatitis, or NASH, might be prevented by treatments able to target certain immune cells, according to a recent study in mice which demonstrated that the condition has…
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
Researchers presented more than 50 studies highlighting the benefits of Accuray’s CyberKnife System at the 36th Annual European Society for Radiotherapy and Oncology (ESTRO)…
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Durect has signed an agreement with Sandoz to develop and market Posimir (Saber-bupivacaine), an investigational localized pain reliever, in the United States. Durect…
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed…
